Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy

Due to the deficient catalase, abundant reduced iron and low acidic environment in lysosomes, inducing lysosomal membrane permeabilization (LMP) through Fenton reaction‐based reactive oxygen species (ROS) generation recently attracts increasing attention in cancer therapy. However, the lysosomal membranes are protected by highly glycosylated membrane proteins and several endolysosomal damage‐response mechanisms can rapidly repair the injured lysosomes. To produce sufficient ROS and cause complete lysosomal membranes rupture, a lysosome‐targeted ROS inducer, N‐(3‐Aminopropyl) morpholine grafted cross‐linked lipoic acid vesicles with vitamin C‐loading (VC@N3AMcLAVs), is developed. VC@N3AMcLAVs efficiently accumulate in lysosomes and convert into two redox couples LA/DHLA (dihydrolipoic acid, reduced form of LA) and VC/DHA (dehydroascorbic acid, oxidized form of VC) by the lysosomal glutathione, which can not only produce a large amount of H2O2 by pro‐oxidant action but also accelerate iron transformation through the cyclic redox reactions between each other and cause the efficient conversion of the generated H2O2 into highly toxic •OH. Both in vitro and in vivo experiments demonstrate that VC@N3AMcLAVs can effectively enhance ROS production and boost LMP, finally initiation irreversible death of tumor cells via ferroptosis pathway, thus representing a potential anticancer drug for cancer therapy. Benefiting from the deficient catalase, abundant reduced iron and low acidic environment in lysosomes, a lysosome‐targeted reactive oxygen species (ROS)‐inducer is established to enhance ROS production ability and boost the lysosomal membrane permeabilization, representing a potential anticancer drug for cancer ferroptosis therapy.